Search PubMed⌕ Search

Biomedical subjects

A A Babaiants

Publications and source records attributed to A A Babaiants.

At least 19 recordsLinked to original sources
PubMed2003

[Effects of immunomodulator leukinferon on the course of experimental tuberculosis].

An experiment was conducted on 60 CBA mice intravenously inoculated with cultured Mycobacteria tuberculosis (MBT), Erdmann strain, in a dose of 0.025 mg. The specific features of tissue, cellular, and biochemical reactions were studied in the lung, liver, and spleen when leukinferon (LF) was included into tuberculosis treatment regimen. LF was shown to have a positive impact on the development of reparative reactions during tuberculous inflammation by reducing the time of abacillation and recovering the structure of diseased organs. By month 3 of follow-up, MBT were not detected in mice receiving antibacterial agents (ABA) and LF, while typical and changed forms of LF were identified in the cytoplasm of alveolar macrophages in mice treated with ABA alone. A specific feature of an inflammatory reaction as a significant proliferation of lymphocytes and macrophages with their ample infiltration of target organs was noted in animals receiving LF. This was followed by the activated production of alpha- and gamma-interferons and by the mobilization of an enzymatic link of anti-oxidant defense under chronic oxidative stress, which led to a reduction of resolution of inflammatory areas and to an increase in survival of animals which had not been given ABA, but treated with LF alone.

Adjuvants, Immunologic↗
PubMed1995

[The use of leukinferon in treating measles in adult patients].

The following mucosal are characteristic of measles in adult patients: dryness in the oral cavity, dryness, desquamation, and fissures in the red edge and in the mouth corners, edema and hyperemia, of the buccal mucosa, macular enanthema on the hard and soft palate, Bel'skiĭ-Filatov-Koplik spots, whitish deposit on the gingiva, edematous and bleeding gingiva, and, as a result of general intoxication, a lingual deposit. Leukinferon, a wide-spectrum immunocorrective drug, was used to improve the efficacy of treatment of adult patients with measles; besides alpha-interferon, it contains other cytokines of the first phase of immune response. Therapy with leukinferon led to a sooner improvement of the general status and a more rapid regression of the disease symptoms, including changes in the buccal mucosa, in comparison with the control leukinferon-untreated group.

Acute Disease↗
PubMed1994

[Leukinferon in the treatment of patients with acute viral hepatitis b].

Leukinferon activity was studied in a controlled trial including 30 patients with acute viral hepatitis. The disease ran a moderate severity course in the majority of the patients. Leukinferon, a combined preparation of natural interferon and cytokines produced by virus-induced leukocytes, has marked immunomodulating properties at moderate antiviral activity. Leukinferon was administered intramuscularly for 10 days according to the following scheme: day 1-1 sample 3 times, day 2-1 ampule 2 times, day 3-10-1 ampule a day (overall 1 x 10(5) U of interferon). Due to leukinferon the symptoms of intoxication declined, hepatic biochemistry normalized more rapidly as well as the period of viremia and antigenemia. Positive clinical trends correlated with interferon system improvement and activation of natural killers. 6 months later complete recovery was registered in all leukinferon-treated subjects.

Acute Disease↗
PubMed1993

[The combined therapy of patients with gonorrheal-chlamydial urogenital infections by leukinferon immunocorrection].

The adjuvant injection of wide-spectrum immunocorrector leukinferon to 45 males with gonorrheal-chlamydial urogenital infection receiving tarivid and doxicicline made the treatment shorter and the number of inflammatory complications and recurrences less numerous. Leukocyte and lymphocyte counts returned to normal values 6 days earlier and so did immunological indices. In control subjects (20 patients) on immunocorrection with tactivin inflammation persisted longer, urogenital complications were not cured, chlamydial recurrences occurred in 10% of the patients, immunological normalization was not reached.

Adjuvants, Immunologic↗
PubMed1992

[Leukinferon in immunological correction of acute inflammatory diseases of the abdominal organs].

Addition of (intramuscular+intravenous) leukinferon (LF) to the schemes for the treatment of acute peritonitis promoted a more rapid positive development of the time course of clinical signs and decreasing of leukocytosis in the presence of a pronounced tendency to normalization of the main immunological indices i. e. the counts of differential T-lymphocytes and T-helper cells. There was also activation of neutrophil phagocytic function. A rapid decrease in objective signs of endotoxicosis was recorded: the intoxication leukocytic index and the level of medium-mass molecules. In parallel with the decrease in the intoxication leukocytic index, there was a decrease in cytosis of the peritoneal exudate. The use of LF in the treatment of elderly patients with acute cholecystitis eliminated the clinical signs and normalized the main laboratory indices without surgical interventions which allowed one to make a planned operation with the minimum risk.

Acute Disease↗
PubMed1990

[Immunomodulating properties of leukinferon].

Tolerance and immunomodulating properties of leukinferon for injections were studied in 13 healthy volunteers. The drug was administered by inhalation and intramuscularly in a single dose of 10,000 MU twice daily for 3 days. Intramuscular injections of the drug were accompanied by a number of side effects: pyrogenicity, weakness, headache, that ceased 8-12 hrs after the drug was discontinued. Despite these side effects, the drug was satisfactorily tolerated. Neither viscera nor systemic disorders nor allergic reactions were detected. T-lymphocytes proved to be the most sensitive to the drug. Leukinferon was found to activate the interferon system. The effect was the most marked in respect of IRL-gamma.

Adjuvants, Immunologic↗
PubMed1984

[Antitoxic effect of leukocytic interferon in in vivo experiments].

Leukocyte interferon of various species origin (human, swine, mice) protected mice from the lethal dose of staphylococcal toxin. Endogenic mouse interferon and exogenic serum mouse interferon had no such effect. The suspension of waste leukocytes had also a protective activity. The results of the study evidence the presence of antitoxic factor in the leukocytes.

Animals↗
PubMedDate not supplied

[Expression of receptors for human alpha- and gamma-interferons on the surface of peripheral blood mononuclear cells in viral infections].

Expression of receptors on peripheral blood mononuclears of donors and patients with viral infections during therapy was studied using FITC-labeled monoclonal antiidiotypical antibodies with the "internal image" of human alpha- and gamma-interferons and monoclonal antibodies to these interferons. Activation of the immune system caused by infection modifies the expression of interferon receptors and leads to appearance of membrane-bound interferons, mainly gamma-interferon.

Animals↗
PubMedDate not supplied

[Tumor necrosis factor in medicinal interferon preparations].

In response to virus induction a culture of donor leukocytes alongside with interferon (IF-alpha) produced a factor of tumor necrosis (TNF). The kinetics of TNF and IF-alpha biosynthesis did not depend on the kind of IF used for priming, was rapid, with maximum production within 7-8 hours. Antibodies to IF-alpha and IF-alpha had no effect on TNF production, while antibody to TNF did not reduce IF-alpha yields. TNF in detectable titres was present in medical preparations of native IF-alpha but was absent in preparations of recombinant IF-alpha and IF-alpha as well as in an injection preparation of IF purified by chemical methods.

Antibodies↗
PubMedDate not supplied

[The humoral immunity system of mice with experimental slow influenzal infection].

The status of the interferon system and level of immunoglobulins were studied in C57BL6 mice with slow influenza infection. These mice showed signs of immunosuppression: low endogenous interferon production, synthesis of alpha- and gamma-interferon by splenocytes of these mice in vitro 4-8 times lower than by those of the controls, lower levels of IgG in the blood serum. These data indicate general suppression of humoral immunity.

Aging↗
PubMedDate not supplied

[Experimental myocardiopathy caused by the herpesvirus].

Mice weighing 18--20 g were inoculated with herpes simplex virus type I. The rate of pathological changes in the myocardium was found to depend on the route of virus inoculation and the time of heart examinations in the infected animals. The development of myocardiopathies was not determined by the virus dose used in the test. An immunosuppressant drug, imurane, reduced the rate of heart affections. Pathomorphological changes in the heart were of parenchymatous-interstitial nature, with the leading role of lesions of myocardium muscle cells proper and secondary development of microcirculation disorders. The rate of heart lesions increased when herpes and influenza viruses were given to mice simultaneously; staphylococcus toxin had the same effect.

Animals↗
PubMedDate not supplied

[Leukocyte interferon reaction in patients with primary immunodeficiencies].

The capacity of leukocytes from children with primary immunodeficiency to produce alpha- and gamma-interferons in vitro was studied. Interferon response of leukocytes in most of the patients examined was found to be practically unchanged. The immunostimulating therapy in some cases exerted a regulating effect on leukocyte capacity for interferon production. It is assumed that the interferon-producing function of T lymphocytes may be preserved in patients suffering from primary immunodeficiency.

Adolescent↗
PubMedDate not supplied

[Pharmacokinetics of interferon administered rectally].

Human leukocyte and recombinant interferon administered rectally to rabbits in a dose of 10,000 units per kilo body weight was found in the blood serum within 30 min. A certain level of interferon persisted for 5 hours after which time it disappeared from the serum. Recombinant interferon was eliminated more rapidly than leukocyte interferon. Repeated administrations of interferon at 5-hour intervals increased the time of its presence in the serum. The rectal method of interferon administration was used clinically in infants under one year. Its pharmacokinetics did not differ from that after administration by other routes.

Animals↗